MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Histogenics Corp Company Profile (NASDAQ:HSGX)

Consensus Ratings for Histogenics Corp (NASDAQ:HSGX) (?)
Ratings Breakdown: 1 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $12.13 (577.37% upside)

Analysts' Ratings History for Histogenics Corp (NASDAQ:HSGX)
Show:
DateFirmActionRatingPrice TargetActions
5/15/2016BTIG ResearchReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Cowen and CompanyLower Price TargetOutperform$17.00 -> $12.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/13/2015Needham & Company LLCLower Price TargetBuy$17.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/26/2014 forward)
Earnings History for Histogenics Corp (NASDAQ:HSGX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/12/2016Q116($0.59)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.59)($0.63)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.47)($0.61)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.49)($0.58)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2015Q115($1.34)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414$0.66$1.70ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Histogenics Corp (NASDAQ:HSGX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Histogenics Corp (NASDAQ:HSGX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Histogenics Corp (NASDAQ:HSGX)
No insider trades for this company have been tracked by MarketBeat.com

Latest Headlines for Histogenics Corp (NASDAQ:HSGX)
DateHeadline
06/22/16 04:02 PMHISTOGENICS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/17/16 07:15 AMManufacturing Stocks Daily Report
05/28/16 12:18 PMHistogenics Corporation (NASDAQ:HSGX) Impact Score At 0 - Investor Newswire - Histogenics Corporation (NASDAQ:HSGX) Impact Score At 0Investor NewswireAlpha One explored various online articles released on Histogenics Corporation (NASDAQ:HSGX), and it set a daily sentiment score of -0.217 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/12/16 06:07 AMQ1 2016 Histogenics Corp Earnings Release - Before Market Open -
05/12/16 05:52 AMBRIEF-Histogenics Corp Q1 loss per share $0.60 - * Histogenics Corporation announces first quarter 2016 financial and operating results
05/12/16 05:41 AMHistogenics reports 1Q loss -
05/12/16 05:30 AMHistogenics Corporation Announces First Quarter 2016 Financial and Operating Results - [GlobeNewswire] - -NeoCart ® Phase 3 Clinical Trial Remains on Track for Enrollment Completion by End of Second Quarter of 2017-. -Company to Host Conference Call and Webcast Today at 8:30 a.m. EDT-. WALTHAM, Mass., May ...
05/10/16 08:16 AMHISTOGENICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits -
05/10/16 08:00 AMHistogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market - [GlobeNewswire] - WALTHAM, Mass., May 10, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it has acquired the ...
05/04/16 04:32 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of Histogencis Corporation -- HSGX - [PR Newswire] - NEW YORK, May 4, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Histogenics Corporation (NASDAQ: HSGX) concerning possible breaches of fiduciary duty by its Board ...
05/04/16 10:20 AMSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Histogenics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors - [PR Newswire] - NEW YORK, May 4, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Histogenics Corporation (HSGX). You may also contact Robert H. Lefkowitz, Esq. Purcell Julie & Lefkowitz LLP is a law firm exclusively committed to representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty and other types of corporate misconduct.
04/28/16 07:30 AMHistogenics Corporation to Announce First Quarter 2016 Financial Results on May 12, 2016 - [GlobeNewswire] - WALTHAM, Mass., April 28, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its ...
03/31/16 07:30 AMHistogenics Corporation To Present At Needham & Company’s 15th Annual Healthcare Conference - [GlobeNewswire] - WALTHAM, Mass., March 31, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Jonathan ...
03/14/16 11:31 AMEdited Transcript of HSGX earnings conference call or presentation 10-Mar-16 1:30pm GMT -
02/26/16 12:55 PMHistogenics Corporation (NASDAQ:HSGX) Short Interest Decreased By 3.73% - Franklin Independent - Histogenics Corporation (NASDAQ:HSGX) Short Interest Decreased By 3.73%Franklin IndependentThe stock of Histogenics Corporation (NASDAQ:HSGX) registered a decrease of 3.73% in short interest. HSGX's total short interest was 25,800 shares in February as published by FINRA. Its down 3.73% from 26,800 shares, reported previously. With 11,400 ...
02/26/16 12:55 PMChanges To Broker Targets On Histogenics Corporation (HSGX) - Share Trading News - Changes To Broker Targets On Histogenics Corporation (HSGX)Share Trading News05/12/2015 – Histogenics Corporation was upgraded to “hold” by analysts at Zacks. The share price of Histogenics Corporation (HSGX) was down -2.06% during the last trading session, with a day high of 2.70. 6944 shares were traded on Histogenics ...Histogenics Corporation to Present at Upcoming Investor ConferencesNasdaqall 5 news articles »
02/25/16 07:30 AMHistogenics Corporation to Present at Upcoming Investor Conferences - [GlobeNewswire] - WALTHAM, Mass., Feb. 25, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Company Management ...
02/02/16 03:18 PMHISTOGENICS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
02/02/16 03:13 PM4:13 pm Histogenics updates on its ongoing NeoCart Phase 3 clinical trial; 50% of patients enrolled - expect to complete enrollment by the end of Q2 2017 -
02/02/16 03:05 PMHistogenics Corporation Provides NeoCart® Phase 3 Clinical Trial Enrollment Update - [GlobeNewswire] - WALTHAM, Mass., Feb. 02, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that as of February 2, ...
01/26/16 07:30 AMHistogenics Corporation to Present at 18th Annual BIO CEO & Investor Conference - [GlobeNewswire] - WALTHAM, Mass., Jan. 26, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, ...
01/06/16 08:01 AMHistogenics Corporation to Present at Biotech Showcase 2016 - WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley ...
01/06/16 07:30 AMHistogenics Corporation to Present at Biotech Showcase 2016 - [GlobeNewswire] - WALTHAM, Mass., Jan. 06, 2016-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, ...
12/21/15 07:31 AMHISTOGENICS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
12/21/15 07:15 AMHistogenics Corporation Announces Amendment to NeoCart® Phase 3 Clinical Trial Enrollment Criteria - [GlobeNewswire] - WALTHAM, Mass., Dec. 21, 2015-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that the United States ...
12/08/15 12:18 PMHISTOGENICS CORP Financials -
11/13/15 08:58 AMEdited Transcript of HSGX earnings conference call or presentation 12-Nov-15 1:30pm GMT -
11/12/15 07:30 AMHistogenics Corp Earnings Call scheduled for 8:30 am ET today -
11/12/15 06:41 AMHistogenics reports 3Q loss -
11/12/15 06:07 AMQ3 2015 Histogenics Corp Earnings Release - Before Market Open -
11/12/15 05:46 AMHISTOGENICS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
11/12/15 05:30 AMHistogenics Corporation Announces Third Quarter 2015 Financial and Operating Results - [GlobeNewswire] - -Completion of Enrollment of NeoCart ® Phase 3 Trial Now Expected in Second Quarter of 2017-. -Company to Host Conference Call and Webcast Today at 8:30 a.m. EST-. WALTHAM, Mass., Nov. 12, 2015-- Histogenics ...
10/29/15 07:30 AMHistogenics Corporation to Announce Third Quarter 2015 Financial Results on November 12, 2015 - [GlobeNewswire] - WALTHAM, Mass., Oct. 29, 2015-- Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced it will release its financial ...
10/01/15 09:58 AMHistogenics Corporation to Participate in Upcoming Scientific and Investor Conferences - [at noodls] - WALTHAM, Mass., October 1, 2015 /GLOBE NEWSWIRE/ - Histogenics Corporation (Histogenics) (Nasdaq: HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal ...
08/14/15 01:54 PMEdited Transcript of HSGX earnings conference call or presentation 12-Aug-15 12:30pm GMT -
About Histogenics Corp

Histogenics Corp logoHistogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company's product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is a cartilage-like implant created using a patient's own cartilage cells through a series of tissue engineering processes. The patient's cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in its laboratory. The cells are then infused into its scaffold that provides structure for the developing implant. Before NeoCart is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in the Company's Tissue Engineering Processor (TEP). The Company has operations in the United States and Israel.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: HSGX
  • CUSIP:
Key Metrics:
  • Previous Close: $1.79
  • 50 Day Moving Average: $1.85
  • 200 Day Moving Average: $2.43
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $23.75M
  • Current Quarter EPS Consensus Estimate: $-2.15 EPS
Additional Links:
Histogenics Corp (NASDAQ:HSGX) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha